Evolent Health, Inc.
NYSE:EVHMedical - Healthcare Information Services
-$0.28 today
- Market cap
- $442.05M
- Beta
- 0.83
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$4.44
Volume 3.10M
Average 2.78M
EVH EBITDA Margin
EBITDA as a percentage of revenue.
Evolent Health, Inc.NYSE: EVH
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to 2.7%
EBITDA Margin was 2.7% in Q1 FY2026, up 8.7 pp from a year earlier. On a trailing-twelve-month basis it was -16.7%, down 18.0 pp year over year. Over 3 fiscal years it narrowed by 22.5 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 10 analysts of 6.9% for the fiscal year ending Dec 2026, up from -19.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 2.7%+81.0 pp QoQ
- Last fiscal yearDec 2025
- -19.3%-22.6 pp YoY
- LTMMar 2026
- -16.7%-18.0 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +8.7 pp | +2.8 pp | -5.9 pp |
| 1 year | -22.6 pp | +26.2 pp | +48.8 pp |
| 3 years | -22.5 pp | +25.0 pp | +47.5 pp |
| 5 years | +25.4 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -19.3%
- Year-over-year change
- -22.6pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -19.3% | -22.6pp |
| FY2024 | 2024-12-31 | 3.3% | +4.6pp |
| FY2023 | 2023-12-31 | -1.3% | -4.5pp |
| FY2022 | 2022-12-31 | 3.2% | -2.9pp |
| FY2021 | 2021-12-31 | 6.1% | — |
EBITDA Margin vs competitors
How EVH compares with its peers on the latest reported figures
- EVH's LTM Mar 2026 EBITDA Margin of -16.7% is the 4th highest of the 9 companies compared; the peer median is -52.6%.
- Its year-over-year change of -18.0 pp is the 6th highest of 9, against a peer median of -1.9 pp.
- Over three fiscal years its change of -22.5 pp compares with a peer median of +77.3 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 33.2% | -1.1 pp | +212.5 pp | |
| LTM Mar 2026 | 22.4% | +0.1 pp | +1.9 pp | |
| LTM Mar 2026 | 5.9% | +4.5 pp | -11.3 pp | |
| LTM Mar 2026 | -16.7% | -18.0 pp | -22.5 pp | |
| LTM Mar 2026 | -40.3% | -32.6 pp | -27.6 pp | |
| LTM Mar 2026 | -64.8% | -2.6 pp | +152.7 pp | |
| LTM Mar 2026 | -120.0% | +290.8 pp | +619.2 pp | |
| LTM Mar 2026 | -132.6% | -47.0 pp | — | |
| LTM Mar 2026 | -408.0% | -146.3 pp | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding EVH) | -52.6% | -1.9 pp | +77.3 pp | |
Competitors are the stored peer set for EVH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 907.96M | 1.35B | 1.96B | 2.55B | 1.88B |
| Cost of Revenue | 657.55M | 1.04B | 1.5B | 2.19B | 1.59B |
| Gross Profit | 250.41M | 316.58M | 460.47M | 367.35M | 284.03M |
| Gross Margin | 27.6% | 23.4% | 23.4% | 14.4% | 15.1% |
| Research & Development | 0 | 27M | 0 | 0 | 0 |
| Selling, General & Admin | 219.5M | 269.27M | 358.11M | 263.05M | 288.47M |
| Operating Expenses | 292.82M | 312.94M | 531.68M | 407.84M | 288.47M |
| Depreciation & Amortization | 60.04M | 90.25M | 123.42M | 123.17M | 115.85M |
| EBITDA | 55.66M | 43.75M | (24.79M) | 84.85M | (361.31M) |
| EBITDA Margin | 6.1% | 3.2% | -1.3% | 3.3% | -19.3% |
| Operating Income | (42.41M) | 3.64M | (71.21M) | (40.49M) | (4.44M) |
| Operating Margin | -4.7% | 0.3% | -3.6% | -1.6% | -0.2% |
| Interest Income | 407K | 1.37M | 5.26M | 5.54M | 4.19M |
| Interest Expense | 25.43M | 15.57M | 54.21M | 24.72M | 57.47M |
| Other Income / Expenses | 12.61M | (65.72M) | (131.19M) | (22.55M) | (530.2M) |
| Income Before Tax | (29.8M) | (62.08M) | (202.41M) | (63.04M) | (534.64M) |
| Pre-Tax Margin | -3.3% | -4.6% | -10.3% | -2.5% | -28.5% |
| Income Tax Expense | 483K | (43.38M) | (89.37M) | (1.41M) | (126K) |
| Net Income | (37.6M) | (19.16M) | (113.04M) | (61.62M) | (534.51M) |
| Net Margin | -4.1% | -1.4% | -5.8% | -2.4% | -28.5% |
| EPS (Basic) | (0.36) | (0.20) | (1.28) | (0.81) | (5.07) |
| EPS (Diluted) | (0.36) | (0.20) | (1.28) | (0.81) | (5.07) |
| Weighted Avg Shares | 86.07M | 93.7M | 111.25M | 114.68M | 114.21M |
| Weighted Avg Shares (Diluted) | 86.07M | 93.7M | 111.25M | 114.68M | 114.21M |
Evolent Health, Inc.
NYSE:EVH
Intrinsic Alpha fair value
Locked
Current Price
$3.93
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.